Precision Biosciences Inc
DTIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357874
In the last 90 days, Precision Biosciences Inc insiders filed 3 open-market purchases and 1 sale; 96 institutions reported holding it in 13F filings for Q2 2026, worth $139.5M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $45.7M (133.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 8, 2025 | Jan 11, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M |
| Operating expenses | $86.4M | $94.9M | $92.5M | $125.5M | $154.9M |
| Research and development | $54.2M | $59.6M | $53.4M | $83.9M | $115.2M |
| Selling, general and administrative | $32.2M | $35.3M | $39.1M | $41.5M | $39.7M |
| Operating income | -$52.1M | -$26.2M | -$43.7M | -$100.4M | -$39.4M |
| Interest expense | – | $1.78M | $2.23M | $1.11M | $132.0K |
| Income tax | $0 | – | – | – | – |
| Net income | -$45.7M | $7.17M | -$61.3M | -$111.6M | -$30.6M |
| EPS, basic | $-3.56 | $1.05 | $-15.96 | $-1.27 | – |
| EPS, diluted | $-3.56 | $1.04 | $-15.96 | $-1.27 | – |
| Weighted shares, basic | 12.8M | 6.83M | 3.84M | 87.9M | – |
| Weighted shares, diluted | 12.8M | 6.88M | 3.84M | 87.9M | – |
| Margins and growth | |||||
| Operating margin | -152.2% | -38.1% | -89.8% | -399.9% | -34.1% |
| Net margin | -133.4% | 10.4% | -125.8% | -444.8% | -26.5% |
| Revenue growth, year over year | −50.1% | +41.0% | +94.1% | −78.3% | +375.7% |
| Net income growth, year over year | −738.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 8, 2025 | Jan 11, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $110.8M | $85.9M | $116.7M | $189.6M | $143.7M |
| Short-term investments | $4.76M | $413.0K | – | – | – |
| Accounts receivable | $0 | $229.0K | $901.0K | $720.0K | $488.0K |
| Total current assets | $118.7M | $95.0M | $136.4M | $199.1M | $161.8M |
| Property, plant and equipment | $1.43M | $3.09M | $6.34M | $20.2M | $25.2M |
| Intangible assets | $1.17M | $622.0K | $400.0K | $1.35M | $2.05M |
| Total assets | $154.4M | $136.4M | $159.8M | $238.2M | $211.5M |
| Accounts payable | $296.0K | $1.31M | $2.97M | $1.23M | $1.14M |
| Total current liabilities | $8.91M | $15.0M | $50.0M | $59.7M | $36.0M |
| Long-term debt | – | – | – | $22.2M | $2.48M |
| Total liabilities | $62.2M | $80.0M | $140.9M | $177.7M | $120.3M |
| Shareholders' equity | $92.2M | $56.4M | $18.9M | $60.4M | $91.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 8, 2025 | Jan 11, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | -$65.8M | -$58.4M | -$84.1M | -$45.8M | -$10.9M |
| Capital expenditures | $85.0K | $250.0K | $1.96M | $3.32M | $5.05M |
| Free cash flow | -$65.9M | -$58.7M | -$86.1M | -$49.1M | -$15.9M |
| Depreciation and amortization | $1.47M | $3.40M | $6.82M | $7.80M | $8.98M |
| Stock-based compensation | $10.2M | $12.6M | $14.0M | $19.2M | $16.5M |
| Investing cash flow | -$634.0K | -$215.0K | $5.83M | -$3.32M | -$5.80M |
| Financing cash flow | $95.2M | $50.5M | $5.39M | $95.0M | $70.5M |
| Net change in cash | $28.7M | -$8.21M | -$72.9M | $45.9M | $53.9M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 29.7% | 18.3% | 28.8% | 76.5% | 14.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 27.9M | +110.7% | SEC |
| Aug 3, 2026 | 27.6M | +134.2% | SEC |
| Apr 30, 2026 | 25.8M | +132.7% | SEC |
| Mar 5, 2026 | 24.7M | +135.9% | SEC |
| Oct 29, 2025 | 13.3M | +72.8% | SEC |
| Jul 31, 2025 | 11.8M | +62.9% | SEC |
| May 8, 2025 | 11.1M | +60.1% | SEC |
| Mar 20, 2025 | 10.5M | +51.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-30 in Q1 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.